Myriota Expands Agreement with Spire Global to Scale its IoT Constellation with 16 More Satellites
VIENNA, Va.--(BUSINESS WIRE)-- Spire Global, Inc. (NYSE: SPIR) ('Spire' or 'the Company'), a global provider of space-based data, analytics and space services, announced an expanded Space Services agreement with Myriota to design, build and operate 16 satellites with enhanced second-generation payloads for the IoT provider.
These new launches will see Myriota's IoT connectivity become operational across 40+ satellites. Since initially partnering in 2021, Myriota has scaled its IoT connectivity platform rapidly and cost effectively by deploying its network software on Spire satellites that are optimized to host and run Myriota's advanced network in space. With this agreement, Myriota is expanding into satellite hardware in space through Spire Space Services.
"In a world where IoT connectivity is increasingly crucial, satellites and space technology are more than just tools; they are foundational to the future of global communication networks," said Theresa Condor, CEO of Spire Global. 'As Myriota's constellation grows, so does our collaboration with them, expanding from software to hardware with payloads that address the critical gaps in IoT communication. With Spire Space Services we are thrilled to continue our long-term work with Myriota in reimagining how the world connects.'
The expansion of Myriota's global space infrastructure will allow for more scalable and reliable IoT connectivity for smart devices worldwide. Myriota customers will have enhanced security, faster data access, reduced latency, and improved device control and firmware updating capabilities.
'Across sectors from agriculture and water to logistics, satellite-connected IoT sensors offer unparalleled insights into operations and are driving dramatic improvements in operational efficiency,' said Ben Cade, CEO of Myriota. 'At Myriota we are working with customers around the globe delivering ultra-low power networks, with sensor battery lives measured in years. We are delighted to be working with Spire to further extend our network to help more industries, in more countries gain critical intelligence from the field, and apply this to deliver better outcomes for industry, society and the planet.'
About Spire Global, Inc.
Spire (NYSE: SPIR) is a global provider of space-based data, analytics and space services, offering unique datasets and powerful insights about Earth so that organizations can make decisions with confidence in a rapidly changing world. Spire builds, owns, and operates a fully deployed satellite constellation that observes the Earth in real time using radio frequency technology. The data acquired by Spire's satellites provides global weather intelligence, ship and plane movements, and spoofing and jamming detection to better predict how their patterns impact economies, global security, business operations and the environment. Spire also offers Space as a Service solutions that empower customers to leverage its established infrastructure to put their business in space. Spire has nine offices across the U.S., Canada, UK, Luxembourg, Germany and Singapore. To learn more, visit spire.com.
About Myriota
Myriota is a global leader in low-cost, low-power, secure direct-to-orbit satellite connectivity for the Internet of Things (IoT), and small power-constrained devices. Founded in 2015, Myriota's space-based network delivers scalable, affordable IoT data services and energy-efficient hardware that is essential for sectors such as agriculture, logistics, water management and environmental conservation. For more information, visit myriota.com. Follow us here: LinkedIn, X, Facebook, YouTube.
Forward Looking Statements
This press release contains forward-looking statements, including information regarding management's view of Spire's future expectations, plans and prospects, including our views regarding future execution within our business, and the opportunity we see in our industry, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Spire to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are included in documents Spire files with the Securities and Exchange Commission, including but not limited to, Spire's Annual Report on Form 10-K/A for the year ended December 31, 2024, as well as subsequent reports filed with the Securities and Exchange Commission. Other unknown or unpredictable factors also could have material adverse effects on Spire's future results. The forward-looking statements included in this press release are made only as of the date hereof. Spire cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Spire expressly disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
OGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting Investors have until July 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Hauser v. Organon & Co., et al. , No. 25-cv-05322. Why was Organon Sued for Securities Fraud? Organon is a global healthcare company focused on women's health that has historically rewarded its shareholders with a healthy dividend. In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company focused on dermatological conditions. As alleged, while the acquisition increased Organon's debt, the Company assured investors it would maintain its dividend, which Organon asserted was its '#1 capital allocation priority.' In truth, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt, ultimately leading the Company to severely cut its dividend. The Stock Declines as the Truth is Revealed On May 1, 2025, Organon announced that management reset the Company's dividend payout from $0.28 per share to $0.02 per share. Organon's CEO explained that the Company 'reset our capital allocation priorities to accelerate progress towards deleveraging' and that '[b]y deleveraging more rapidly, we will continue to strengthen the future prospects of the company.' Organon's CFO added, '[t]he biggest issues we face . . . relate to managing our leverage and relate to growth. And we need capital to solve both of those issues, and so returning capital to shareholders is right now, less of a priority.' On this news, the price of Organon stock declined roughly 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025. Click here if you suffered losses: What Can You Do? If you invested in Organon you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
an hour ago
- Business Upturn
IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al. , No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company's authorized treatment centers ('ATCs'). As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance's ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs. The Stock Declines as the Truth is Revealed On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was 'revising full-year 2025 revenue guidance.' The Company blamed 'recent launch dynamics,' including slow 'treatment timelines for new ATCs' and 'the variable pace at which ATCs began treating patients,' which 'differs from center to center.' Iovance also blamed the poor results on high 'patient drop-off' due to inadequate 'patient selection' for treatment. On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025. Click here if you suffered losses: What Can You Do? If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
an hour ago
- Business Upturn
RDDT FRAUD ALERT: Reddit, Inc. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by August 18 Legal Deadline (NYSE:RDDT)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Reddit, Inc. (NYSE: RDDT) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Reddit, you are encouraged to obtain additional information by visiting: Investors have until August 18, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Reddit securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Tamraz, Jr. v. Reddit, Inc., at al. , No. 25-cv-05144. Why was Reddit Sued for Securities Fraud? Reddit owns and operates the eponymous social news aggregation, forum, and social media platform. Reddit receives a significant portion of its user traffic from individuals seeking answers to questions using Google Search. The complaint alleges that Reddit misrepresented and downplayed the impact that Google's use of Artificial Intelligence ('AI') technology in Google's search results had on Reddit's user growth. In truth, Google's use of AI dented Reddit's user growth by eliminating the need for individuals to visit and click through to Reddit to get answers to their questions. Rather, the answers appeared through Google's AI search results. The Stock Declines as the Truth is Revealed On May 1, 2025, Reddit reported a significant slowdown in daily active user growth. On this news, the price of Reddit stock declined $4.96 per share, or more than 4%, from $118.79 per share on May 1, 2025, to $113.83 per share on May 2, 2025. Then, on May 21, 2025, Wall Street analyst Baird cut its Reddit stock price target over concerns that Google's AI capabilities are stifling Reddit's user growth. On this news, the price of Reddit stock fell $9.79 per share, or over 9%, from $105.64 per share on May 20, 2025, to $95.85 per share on May 21, 2025. Click here for more information: What Can You Do? If you invested in Reddit you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
